Immune Tolerance Network (ITN)

What is ITN?

The Immune Tolerance Network (ITN) is an international consortium dedicated to evaluating new treatments for autoimmune diseases, asthma, and allergic diseases, and to preventing the rejection of transplanted kidneys and pancreatic islets

ITN Objectives

The primary aim of the Immune Tolerance Network (ITN) is to investigate the mechanisms of action of therapies and strategies aimed at inducing immune tolerance. This includes assessing the safety and efficacy of islet transplantation for brittle type 1 diabetes and determining efficacy as measured by insulin independence at one-year post transplant, assessing the safety and efficacy of an anti-CD3 antibody to prevent the loss of insulin producing cells in new-onset diabetes and induce long-term immunologic tolerance to autoantigens associated with type 1 diabetes, evaluating the safety of the human insulin B chain in newly diagnosed type 1 diabetes, and evaluating the efficacy of an anti-CD52 antibody and an anti-CD3 antibody to promote the induction of tolerance to transplanted pancreatic islets.

ITN Centers

The ITN is composed of more than 80 basic and clinical scientists and physicians, co-funded by the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases and the Juvenile Diabetes Research Foundation, at over 40 institutions in the U.S., Canada, and Europe.